Kolexia
Miglianico Laurent Oncologie radiothérapie
Miglianico Laurent
Oncologie radiothérapie
Clinique De La Cote D'emeraude
Saint-Malo, France
73 Activités
265 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Adénocarcinome Tumeurs du côlon Métastase tumorale Tumeurs du pancréas Tumeurs de la prostate Tumeurs de l'anus Tumeurs de l'oesophage Paronychie

Collaborateurs

Voir plus
Mineur Laurent
Mineur Laurent
Centre Hospitalier de Apt, Apt, France
Bouche Olivier
Bouche Olivier
Hôpital Robert-Debré Reims, Reims, France
Francois Eric
Francois Eric
Centre Antoine Lacassagne, Nice, France
Taieb Julien
Taieb Julien
Hôpital Européen Georges Pompidou, Paris, France

Industries

Voir plus
Novartis
6 collaboration(s)
Dernière en 2022
GSK
2 collaboration(s)
Dernière en 2023
MSD
1 collaboration(s)
Dernière en 2022
Lilly
1 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
JAMA network open   05 septembre 2023
IROCAS: A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-risk Stage III Colon Cancer in Adjuvant Setting
Essai Clinique (Unicancer)   30 août 2023
OSCAR: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
387P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Final results of the randomized phase II TIME-PRODIGE 28 UNICANCER study
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
TIME: Randomized Phase II Study of First-line FOLFIRI Plus Cetuximab for 8 Cycles Followed by Either Single-agent Cetuximab as Maintenance Therapy or Observation in Patients With Wild-type KRAS and NRAS Metastatic Colorectal Cancer
Essai Clinique (Unicancer)   23 mars 2022
Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab: Phase II, Multicentric Randomized Trial, Evaluating the Efficacy of Fluoropyrimidine-based Standard Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab
Essai Clinique (Unicancer)   07 janvier 2022
429P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: First results of the randomized phase II TIME-PRODIGE28 UNICANCER study according to RAS/BRAF status
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Results of the randomized phase II PRODIGE 28-time UNICANCER study.
2021 Gastrointestinal Cancers Symposium   22 janvier 2021
PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer.
PloS one   21 décembre 2020
MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma FNCLCC-FFCD-AGEO PRODIGE 17-ACCORD 20 Randomized Phase II Trial
Essai Clinique (Unicancer)   13 novembre 2020